Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) and CollPlant Holdings Ltd. (NASDAQ:CLGN), are influenced by compare since they are both players in the Biotechnology. These factors are particularly influence the dividends, analyst recommendations, institutional ownership, profitability, risk, earnings and valuation of the two firms.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Diffusion Pharmaceuticals Inc. N/A 0.00 26.62M -6.72 0.00
CollPlant Holdings Ltd. N/A 0.00 N/A -1.64 0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 shows us the return on assets, return on equity and net margins of both businesses.

Net Margins Return on Equity Return on Assets
Diffusion Pharmaceuticals Inc. 0.00% -79.1% -69.4%
CollPlant Holdings Ltd. 0.00% 0% 0%

Institutional and Insider Ownership

Roughly 8.9% of Diffusion Pharmaceuticals Inc. shares are held by institutional investors while 23.69% of CollPlant Holdings Ltd. are owned by institutional investors. Diffusion Pharmaceuticals Inc.’s share held by insiders are 3.37%. Insiders Comparatively, held 19.13% of CollPlant Holdings Ltd. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Diffusion Pharmaceuticals Inc. 10% 55% -21.74% -40.8% -62.73% 71.36%
CollPlant Holdings Ltd. -7.86% -12.98% -11.03% -7.19% 0% 22.86%

For the past year Diffusion Pharmaceuticals Inc.’s stock price has bigger growth than CollPlant Holdings Ltd.

Summary

CollPlant Holdings Ltd. beats Diffusion Pharmaceuticals Inc. on 4 of the 6 factors.

Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, developing small-molecule drugs that help regulate the movement of oxygen into tissue by a novel mechanism of action. Its lead product candidate is trans sodium crocetinate, which is in Phase I/II clinical trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer; and Phase II/III clinical trials for the treatment of metastatic brain cancer. The company is also developing RES-529, a novel PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of macular degeneration; and is in pre-clinical development in oncology applications primarily GBM. Diffusion Pharmaceuticals Inc. is headquartered in Charlottesville, Virginia.

CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. Its products are based on recombinant type I human collagen (rhCollagen) that is produced with its proprietary plant based genetic engineering technology. The company’s products include Vergenix STR, a soft tissue repair matrix intended for treatment of tendinopathy; Vergenix FG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. and is headquartered in Ness Ziona, Israel.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *